Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements (Details)

v3.21.2
Collaboration and License Agreements (Details)
$ in Thousands
1 Months Ended 9 Months Ended
Mar. 10, 2020
USD ($)
Jul. 31, 2021
USD ($)
shares
Apr. 30, 2021
USD ($)
Sep. 30, 2021
USD ($)
Country
Milestone
BioSense License and Assignments Agreement [Member]        
Collaboration and License Agreement [Abstract]        
Upfront payment received $ 1,650      
Milestone payment achieved for performance obligation, recorded as collaboration revenue       $ 100
Milestone payments received   $ 50 $ 50 0
Maximum amount of payments receivable for development, regulatory and commercial milestones       84,500
BioSense License and Assignments Agreement [Member] | Rexahn [Member]        
Collaboration and License Agreement [Abstract]        
Upfront payment received $ 1,550      
Processa License Agreement [Member]        
Collaboration and License Agreement [Abstract]        
Upfront payment received   $ 200    
Milestone payments received       $ 0
Upfront payment received in common shares (in shares) | shares   44,689    
Upfront payment received in common shares   $ 342    
Period of restriction from selling common stock       1 year
Number of times sales milestone payments | Milestone       1
Percentage of milestone payments eligible to receive on sub-license agreement       32.00%
Number of countries | Country       1
Milestone period to administer drug clinical trial of licensed product on first patient       3 years
Milestone period to administer drug clinical trial of licensed product on first patient for second indication       5 years
Period of opportunity to cure breach of agreement       120 days
Period of prior written notice to be served for termination of agreements       120 days